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Abstract
Background: A minority of European countries have participated in international comparisons with high level data
on lung cancer. However, the nature and extent of data collection across the continent is simply unknown, and
without accurate data collection it is not possible to compare practice and set benchmarks to which lung cancer
services can aspire.
Methods: Using an established network of lung cancer specialists in 37 European countries, a survey was distributed
in December 2014. The results relate to current practice in each country at the time, early 2015. The results were
compiled and then verified with co-authors over the following months.
Results: Thirty-five completed surveys were received which describe a range of current practice for lung cancer
data collection. Thirty countries have data collection at the national level, but this is not so in Albania, Bosnia-
Herzegovina, Italy, Spain and Switzerland. Data collection varied from paper records with no survival analysis, to
well-established electronic databases with links to census data and survival analyses.
Conclusion: Using a network of committed clinicians, we have gathered validated comparative data reporting an
observed difference in data collection mechanisms across Europe. We have identified the need to develop a well-
designed dataset, whilst acknowledging what is feasible within each country, and aspiring to collect high quality
data for clinical research.
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Background
Whilst Europe contains one eighth of the world’s popu-
lation, it accounts for a quarter of all reported cases of
cancer [1]. Lung cancer remains the commonest cause
of death from cancer in both men and women across
Europe and has one of the worst prognoses of all can-
cers [2]. It constitutes an enormous health burden across
the continent and its incidence corresponds to the his-
toric tobacco smoking rates. In the absence of a thera-
peutic breakthrough, the cancer community must ensure
that it implements current best practice as effectively as
possible. Our priorities should be to improve outcome
by: reducing smoking prevalence through public health
campaigns, improving early diagnosis, eradicating in-
equality in access to investigations and treatment, assur-
ing access to novel therapies and reducing the number
of patients who present via the emergency department
when their prognosis is much worse [3].
Several publications have documented a variation in
outcome from lung cancer across Europe in the last
15 years [2, 4], but there has been minimal attention to
correlating these differences in outcome with clinical
practice and clinical resources. It is not clear how much
this variation depends on the historical, cultural and pol-
itical background of a country. The number of inde-
pendent countries in Europe has significantly increased
in the last twenty-five years, and there is a self-evident
wide variation in population size, economic stability and
healthcare infrastructure. As an example of the diverse
healthcare infrastructure in Europe, Table 1 illustrates
the variation in access to primary care which was re-
corded in 2011 [5]. Without this information, it is diffi-
cult to make comparisons between countries, and
impossible to learn from different practices and identify
the key elements within the whole pathway that limit
the implementation of an optimal standard of care in
each country.
A recent taskforce of the European Respiratory Society
(ERS) entitled European Initiative in Quality Management
in Lung Cancer Care (EIQMLCC) provided evidence of
the extent of variation in healthcare infrastructure, and
also performed a feasibility study, the European Lung
Cancer Audit (EuLuCA), collecting prospective data on
patients with a new diagnosis of lung cancer [6]. Data col-
lection is a key component in quality management and al-
lows accurate evaluation of the epidemiological trends
over time and a meaningful analysis of the variation in
clinical care provision. However, despite this being a rec-
ommended approach [7], datasets currently developed for
international use are likely to be beyond the ability of the
majority of European countries to populate. This study
aims to benchmark the European position in relation to
the feasibility of collecting pan-European data by assessing
the current practice with respect to data collection, and
also to gauge the feasibility of, and interest in, a
pan-European database for thoracic malignancy.
Methods
Based on the network of lung cancer specialists
established during the EIQMLCC taskforce who had
participated in the EuLuCA project, a survey was distrib-
uted to 37 European countries in December 2014 (see
Additional file 1). This survey was designed by the
co-authors specifically to investigate the current status of
data collection in Europe. The participants, all lung cancer
physicians, gave written consent to participate in the pro-
ject. They were also asked their opinion on 3 qualitative
questions: what key challenges to prospective thoracic on-
cology data collection exist in their country; what is re-
quired to improve data acquisition and whether they
would be willing to participate in a pan-European data
collection programme.
Results
Thirty-five of 37 countries returned completed surveys,
a response rate of 95%. The participating countries are
shown in Table 2; they comprise countries with a variety
of socio-political structures and represent 64% of all
European countries, as defined by the World Health Or-
ganisation. The countries within our cohort represent
68% of the population of Europe, or 93% of the popula-
tion if Russia and the other former states of the USSR
are excluded. Several countries of the former USSR fall
within the region of central Asia, despite the WHO in-
clusion within Europe. Co-authors also sent examples of
data collection forms, annual reports and the contact de-
tails of the individuals responsible for data collection in
thoracic oncology in their country (Additional file 2).
National data collection
Thirty countries collect data on a national level, with the
majority using a national registry for all cancers. Several
countries have a data collection programme for lung
cancer in addition to a Cancer Registry, namely: Denmark,
England and Wales, Germany, Hungary, The Netherlands,
Norway, Scotland and Slovenia. Other countries have a
specific thoracic surgery database, such as France, The
Netherlands and Norway. There is no universal national
data collection for lung cancer in Albania, Bosnia
Herzegovina, Italy, Spain and Switzerland. The Albanian
Respiratory Society has a register of lung cancer patients;
described as a labour intensive paper record completed by
senior doctors, and with limited clinical and survival data,
with no formal analysis. There are two entities to Bosnia
Herzegovina, the Federation of Bosnia Herzegovina and
the Republic of Srpska. There is regional data collection
for all cancers in Bosnia Herzegovina, with data collected
electronically by the Federal Institute of Public Health.
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Table 1 Access to primary care (survey from 2011 part of ERS taskforce) [5]
Country Remarks
“free for everyone”
Austria
Belarus
Denmark
Hungary
Ireland For those individuals with a ‘medical card’.
Italy
Kyrgyzstan
Lithuania
Malta
Poland
Portugal
Spain
Turkey
Ukraine
United Kingdom
“free but Insurance pay”
Albania Single level of Health Insurance which is mandatory in order to allow access to public hospitals. Additional voluntary Health Insurance in
order to access private hospitals.
B & H Public health care is organised at the cantonal level; with Insurance paid by employers to the Public Fund.
Croatia Two levels of Health Insurance, basic and additional.
Czech Republic
Estonia There is a State-run Health Insurance.
Netherlands Mandatory basic level of Health Insurance which is paid by everyone in employment. There are voluntary supplements available too.
Romania National Public Health Insurance agency.
Serbia Mandatory Social Health Insurance Scheme.
Slovakia Mandatory Health Insurance, paid for by employer or State. 3 companies at present, 1 State run, 2 are private.
Slovenia Health Insurance scheme run by the Government
Switzerland Compulsory Basic level of Health Insurance. Additional ‘complementary’ health Insurance available too.
“Pay at time of consultation”
Bulgaria 1.2E assuming individual paid contribution to National Health Fund. If not met contributions to National Health Fund then 10-15E.
Cyprus Given inadequate Primary care physicians, if choose to see one privately will have to pay 50E.
Germany 10E per visit, or 40E per year and consultations are free.
Iceland 4E. Department of Health covers the rest via taxation.
Ireland If not got a medical card (see above) then pay 60E. Some or all of this can be claimed from private Insurance scheme (50% population.
Norway 22E per visit, up to maximum of 260E per year including primary and secondary care appointments and prescription charges etc. In-patient
stay is free. Government does collect income tax of which some goes to Department of Health.
Sweden 24E per visit, up to maximum of 180E per year.
“Pay a certain amount/proportion”
Belgium 10% paid by patient, 90% paid by ‘social security’.
Finland 13.7E/visit for first 3 visits, then free.
France 23E at time of appointment but individual can claim back 70% of this from Social Security.
Greece 3-10E
Luxembourg Individual pays 20% of 39.9E (ie 8E). Compulsory Public Health and Longterm Care Insurance means Government pays 80% of primary
and secondary care consultation costs.
B & H Bosnia Herzegovina. E Euros
Rich et al. BMC Cancer         (2018) 18:1144 Page 3 of 12
However, there is no data collection in the Republic of
Srpska. In Italy there are 43 local cancer registries, of
which 38 collect data on all cancer types, but 5 registries
collect data on only certain cancer types, or for certain age
groups. In contrast, there is national data collection for
patients with mesothelioma in Italy, via the National Insti-
tute for Insurance against Accidents at Work (INAIL).
The absence of national data collection in Spain and
Switzerland is related to health care infrastructure. In
Spain, there are 17 autonomous communities who control
Table 2 Basic features of data collection in 35 European countries
Year est. Mandatory Consent Form Verbal other Data Completeness (%) Year Histo only Clinical C-R DCO
Albania 2011 No No 90% 2013 No Yes Yes No
Austria 1969 Yes No Not available N/A Yes
Belgium 2006 Yes No 90–94 2013 No Yes Yes
B & H 2004 Yes No 59 2011 No Yes Yes Yes
Bulgaria 1952 Yes No 70–79 2011 Yes
Croatia 1959 Yes No 80–89 2013 Yes
Czech Rep 1977 Yes No 95–100 2013 No Yes Yes No
Denmark 2000~ Yes No 95–100 2013 No Yes Yes Yes*
Eng & Wales 2003~ Yes No 95–100 2013 No Yes Yes No*
Estonia 1953 Yes Yes Yes 95–100 2011 No No Yes Yes
Finland 1953 Yes No 95–100 2012 No Yes Yes Yes
France 1975 No No < 50% 2013 No* No Yes No
Germany 1929 Yes Yes Yes 70–79 2013 No Yes Yes Yes
Greece 2013 Yes No < 50% 2013 No Yes Yes Yes
Hungary 1970~ Yes No 70–79 2013 Yes
Iceland 1955 Yes No 95–100 2013 No Yes-rarely Yes Yes-rarely
Rep. Ireland 1991 No No 90–94 2012 No No Yes Yes
Italy 1996 No Yes Yes 51 2013 Yes
Lithuania 1984 Yes No 95–100 2013 No Yes-rarely Yes Yes-rarely
Luxembourg 2013 Yes Yes implicit Not available N/A No Yes Yes Yes
Malta 1957 Yes No 95–100 2013 No Yes Yes Yes-rarely
Moldova 1983 Yes Yes Yes 50–59 2012 Yes
Netherlands 1989 No Yes implicit 95–97 2013 No Yes Yes No
Norway 1953 Yes No 97 2009 No Yes Yes Yes
Poland 1952 Yes No 80–89 2012 Yes
Portugal 1988 Yes No 60–69 2011 No Yes Yes Yes
Romania 1981 Yes No < 66% 2011 No Yes Yes Yes
Scotland 1958 Yes No 95–100 2013 No Yes Yes Yes
Rep. Serbia 1990 Yes No 60–69 2013 No No Yes Yes (PM)
Slovakia 1952 Yes No 70–79 2008 No No Yes Yes
Slovenia 1950 Yes No 90–94 2010 No Yes Yes Yes
Spain 1960 No Yes Yes Not available N/A No No Yes No
Sweden 1958 Yes No 95–100 2013 No No Yes No
Switzerland 1969 No No 95–100 2013 No Yes Yes Yes
Turkey 1993 No No < 50% 2009 No Yes Yes No
Countries not in bold do not have a national dataset. B&H Bosnia and Herzegovina. DCO death certificate only. N/A not applicable. PM post-mortem only. Year est.;
year that registry established
~ = Lung cancer specific data collection established. Histo only; only those patients with a histological or cytological diagnosis are recorded in the dataset. If no,
then are cases confirmed on clinical grounds alone, or clinico-radiological grounds (C-R), and finally are cases included if the diagnosis of lung cancer is based on
the death certificate only (DCO). Denmark; DCO*; accepted as diagnosis in National Cancer Registry, not in the National Lung Cancer Registry. England and Wales;
DCO*; accepted as diagnosis in the National Cancer Registry not in the National Lung Cancer Audit. France; The Epithor surgical database would be histological
confirmed cases only, the National Cancer Registry is not
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their own healthcare, and set their own agendas and prior-
ities. In Switzerland, there are 26 cantons (regions) cov-
ered by 18 local cancer registries without a nationally
defined dataset; currently only 15 of the 18 registries com-
bine data at a national level.
Basic features
Table 2 illustrates the basic features of these collection
systems, showing the year cancer registration was estab-
lished and where data collection is mandatory, and
where patient consent is required. Data collection in half
of our surveyed countries began between 1950 and 1980;
with another nine countries starting between 1980 and
2000. Bosnia Herzegovina is the only country without a
national data collection programme, but where data col-
lection is mandatory at a regional level, in the Federation
of Bosnia Herzegovina. Of those countries with a na-
tional programme for data collection, reporting is not
mandatory in Germany, Rep. Ireland, the Netherlands
and Turkey. Patient consent is required in 7 of the 35
countries, some at national and some at regional level.
In some countries, such as Slovenia, Slovakia and
Belgium, consent is not required for the national cancer
registry, however patients need to consent for their data
to be entered into the regional/hospital based lung can-
cer registries.
Data completeness
Data completeness reflects the percentage of individuals
with lung cancer reported in the regional or national
datasets, as a percentage of the expected number of
cases of lung cancer in that country, per year. It was
quite variable. Seventeen of 35 countries reported com-
pleteness of > 90%. Bosnia Herzegovina, Greece, Italy,
Moldova and Turkey reported data completeness of less
than 60%, and in France although the data collected on
patients in the Cancer Registry is below 50% complete;
hospital records, collecting non-individualised data are
95–100% complete. Portugal, Romania and Rep. Serbia
report data completeness between 60 and 69%, and
Bulgaria, Germany, Hungary and Slovakia report com-
pleteness between 70 and 79% and Croatia and Poland
report completeness between 80 and 89% (see Table 2).
These data were based on the most up-to-date complete
year of data collection, at the time of the survey, and are
based on national or regional reports or publications.
They were unavailable in three countries, Austria,
Luxembourg and Spain.
Data items
Twenty-eight countries include all patients diagnosed
with histology, cytology or on the basis of clinical and
radiological evidence. Seven countries (20%) collect data
on only those patients with histologically confirmed
disease, excluding other patients (Austria, Bulgaria,
Croatia, Hungary (Koranyi pulmonology registry), Italy,
Moldova and Poland). In contrast, some countries ex-
tend their denominator and also include those diagnosed
on death certificate only, although some required con-
firmation at post-mortem.
Table 3 illustrates the data items collected by each
country. Every country, except Austria, included date of
diagnosis and sex, and all except Hungary and Republic
of Serbia collected date of birth. These two countries
record age at diagnosis instead. Every country records
histology, and almost all use the WHO International
Classification of Diseases for Oncology, 3rd edition.
However in Denmark the SNOMED (Systematized No-
menclature of Medicine) system is used. Almost every
country uses the ERS/ATS/IASLC system to classify
adenocarcinoma [8]; exceptions were Germany, Malta,
Moldova, Romania and Switzerland. Every country ex-
cept Austria, Iceland and Malta record both TNM status
and stage. Performance status (PS) was recorded in less
than half of the countries surveyed. Belgium, Czech Re-
public, Denmark, England and Wales, France, Germany,
Rep. Ireland, Luxembourg, Moldova, Norway, Poland,
Scotland, Rep. Serbia and Sweden recorded PS in a na-
tional registry; whereas Albania, Italy and Spain record
PS at a regional level. A similar number of countries rec-
ord the smoking status of a patient. This information,
however basic (current, ex, or never smoker), was re-
corded in: Austria, Croatia, Czech Republic, Denmark,
Greece, Rep Ireland, Luxembourg, Moldova, Poland,
Sweden and Turkey. Albania, Italy and Spain record
smoking status at a regional level. The lung cancer regis-
try of Slovenia, with 2/3 coverage, collects PS, smoking
status, co-morbidity and molecular markers, although
the national cancer registry does not. Socio-economic
status (SES) was only recorded in five national datasets,
namely: Denmark, England and Wales, Moldova, Poland
and Scotland (calculated from patient’s postcode).
Albania and Italy recorded SES at a regional level. Some
countries record the occupation of an individual which
could be used to infer their SES (Finland, the Republic
of Ireland, Lithuania, Slovakia and Slovenia). In Norway,
information on income and educational status can be
obtained from Statistics Norway and the Norwegian pa-
tient register which can be linked to the Cancer Registry.
It was not feasible to define which of these data items
were mandatory in each country.
Lung function, either spirometry or transfer factor, was
only recorded in Albania, Denmark, England and Wales
and at a regional level in Spain. Co-morbidity was only re-
corded in 9 countries as routine practice, although the ma-
jority did report this feature in research projects. Table 4
illustrates the different measures of co-morbidity, perform-
ance status and quality of life (QOL) used across Europe.
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The Charlson Index [9] and ACE-27 [10] were the most
popular methods for recording co-morbid state. Denmark
is the only country to record data on quality of life (QOL)
at diagnosis and after treatment. In the Czech Republic,
data on QOL is recorded at diagnosis, and the majority of
countries record QOL in the research setting only.
Recording the treatment given to a patient was not
universal; neither was confirming discussion at a
multi-disciplinary team (MDT) meeting. In fact, it
appears MDTs are not mandatory in Romania; they
exist in certain centres, but there is no strict guid-
ance as to their composition. Almost every country
Table 3 Data items collected in current practice in 35 European countries
Date dx Histo TNM Stage PS Smoking comorbid SES FEV1 KCO EGFR EML-4-ALK MDT 1st
line
2nd
line
Last info
date
Date of
death
Albania XXX XXX XXX XXX XXX XXX XXX XXX XXX
Austria XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX
Belgium XXX XXX XXX XXX XXX XXX XXX
B & H XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX
Bulgaria XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX
Croatia XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX
Czech Rep XXX XXX XXX
Denmark OOO
Eng & Wales XXX XXX XXX XXX
Estonia XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX
Finland XXX XXX XXX XXX XXX XXX XXX XXX XXX
France XXX XXX XXX XXX XXX XXX XXX XXX
Germany XXX XXX XXX XXX XXX XXX
Greece XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX
Hungary XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX
Iceland XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX
Rep. Ireland XXX XXX XXX XXX XXX XXX
Italy XXX XXX XXX
Lithuania XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX
Luxembourg XXX XXX XXX XXX
Malta XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX
Moldova XXX XXX XXX XXX
Netherlands XXX XXX OOO XXX XXX XXX XXX XXX XXX
Norway XXX XXX XXX XXX XXX
Poland XXX XXX XXX XXX
Portugal XXX XXX XXX XXX XXX XXX
Romania XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX
Scotland XXX XXX XXX XXX XXX XXX XXX
Rep. Serbia XXX XXX XXX XXX XXX XXX XXX XXX
Slovakia XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX
Slovenia XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX
Spain XXX
Sweden XXX XXX XXX XXX XXX XXX XXX
Switzerland XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX
Turkey XXX XXX XXX XXX XXX XXX XXX XXX XXX
Legend: White box means data item is collected. XXX means data item is not currently collected. OOO means data item only sometimes collected
B&H Bosnia Herzegovina. Date dx date of diagnosis. Histo histological subtype. PS performance status. Comorbid co-morbidity. SES socioeconomic status. KCO
transfer factor. MDT multidisciplinary team. 1st line and 2nd line refer to treatment given. Last info date = follow-up data recorded up to point of death or
censorship for annual report
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recorded a date of death, the only exceptions at the
time of the survey were; Albania, Estonia, Greece
and Hungary.
Qualitative results
There were a number of themes which emerged when
the national representatives were asked what the key
Table 4 Illustrates the variation in methods used to record performance status, co-morbidity and quality of life
Performance status Co-morbidity Quality of Life (QOL)
ECOG/WHO Karnofsky Charlson ACE 27 Specific Other EORTC FACT-G SF-36 FACIT Other
Albania Yes Yes Yes None
Austria Yes Research Research
Belgium Yes Yes Yes*
B & H Yes Yes Yes
Bulgaria Yes Yes** Yes Yes*
Croatia Yes Yes Yes None
Czech Rep Yes None Yes Yes
Denmark Yes Yes Yes Yes EORTC LC13
Eng & Wales Yes Yes Yes No* Yes* Yes*
Estonia Yes* Yes* None None
Finland Yes Yes** Yes Research
France Yes Yes Yes
Germany Yes Yes Yes* Yes*
Greece Yes Yes Yes* Yes* Yes* Yes* Yes* Yes* Yes*
Hungary Yes Yes None
Iceland Yes Yes Yes*
Rep. Ireland Yes None Yes* Yes*
Italy Yes Yes Yes Yes
Lithuania Yes None None
Luxembourg Yes Yes None
Malta Yes Yes Yes Yes
Moldova Yes None Yes
Netherlands Yes Yes Yes*
Norway Yes Yes* Yes Yes** Yes** Yes**
Poland Yes Yes Yes
Portugal Yes Yes** Yes Yes*
Romania Yes None None
Scotland Yes SLCFCSS Yes*
Rep. Serbia Yes Yes** Yes**
Slovakia Yes Yes Yes Yes*
Slovenia Yes Yes None
Spain Yes Yes None
Sweden Yes No** Yes
Switzerland Yes Yes Variation
Turkey Yes Yes None Yes* Yes*
Legend: Charlson = Charlson Index [9]
ACE 27 Adult Co-morbidity Evaluation score [10], SLCFCSS Scottish Lung Cancer Forum Co-morbidity Scoring System [45], Specific specific co-morbid diseases are
recorded, EORTC QLQ-C30 European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire [46], FACT-G Functional Assessment Cancer
Therapy-General [47], SF-36 Short Form-36 [48], FACIT Functional Assessment Chronic Illness Therapy [49]
Yes* = research/clinical trials only
Yes** = infrequently
No* = no longer used
No** = Co-morbidity recorded only if it prevented planned treatment
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challenges were to universal data collection in their own
country. Healthcare infrastructure with closer links be-
tween private and public sectors was cited as a require-
ment to facilitate a common hospital dataset with a
unique patient identifier. Technological limitations, with
no electronic patient record, and inadequate personnel
to support a national dataset were issues for some. Mo-
tivation and education of clinicians was also identified as
a barrier to universal uptake. Finally there was an ac-
knowledgement from some that funding would be the
key challenge, and a concern regarding the legality of a
national patient dataset (Figure 1).
However, there was a very clear positive response to-
wards the idea of a pan-European dataset of thoracic on-
cology. Twenty of the participants gave a definite positive
response to this aspiration (57%), and a further 5 (14%)
confirmed they would be keen if there were enough re-
sources and assuming this did not result in duplication of
work. Another 5 (14%) participants would support this
work if there was national agreement, or it was made
mandatory. One participant was quite neutral, and only 2
(6%) were opposed to the idea of a pan-European dataset.
Discussion
Main findings
The main finding of this study is that data are being col-
lected in the majority of European countries, but the
nature, extent, and hence the usefulness of these data
varies considerably. Surprisingly some basic demo-
graphic items as well as important factors predictive of
outcome were omitted in some datasets, and do not
form part of the European Network of Cancer Registries’
(ENCR) recommendations [11, 12]. Socio-economic sta-
tus and performance status are two of the most import-
ant predictors of outcome [13–17], yet data recording
and completeness of these data items was highly vari-
able. The majority of countries already use computerised
reporting, with linkage to demographic information re-
sources which allows survival analyses to be performed.
However, in Albania, Estonia, Greece, Hungary, Malta
and Romania these survival data are not collected, and
the use of paper records remains current practice in
Albania, Croatia, Lithuania and Romania. Many coun-
tries have a cancer registry, with good levels of data
completeness, but they often lack the level of clinical de-
tail required for evaluating quality management in thor-
acic oncology care.
We identified significant and important differences in
the denominator used. The exclusion of cases which lack
histological confirmation will make comparisons difficult
because the size of the denominator will depend on the
histological confirmation rate. Furthermore those coun-
tries that allow inclusion of death certificate only cases
will have a comparatively poor outcome. It is clear from
these two findings (variation in data items collected and
denominator) that there needs to be agreement between
interested parties (such as the ENCR, respiratory, oncol-
ogy and surgical societies) on both patients included and
the list of data items with specific definitions, ensuring
feasibility of data collection in each country.
Another important finding from this survey is that
within this selected group of clinicians, with only two
exceptions, there was support to create a pan-European
core dataset for thoracic oncology. This is an important
area of development and one which demands the in-
volvement of committed clinicians representing all
disciplines.
Strengths and weaknesses
The main strength of this study is the high level of par-
ticipation including 35 European countries. This has
generated a comprehensive description of current prac-
tice in data collection in thoracic oncology from all areas
of Europe. It is difficult to verify the self-reported data
completeness levels given several countries do not report
their data quality, and in those countries where data col-
lection occurs at the local level, it is difficult to ensure
we have correctly reported the data items used. A survey
can only ever be descriptive and could be open to bias,
but all the national representatives are physicians in-
volved in thoracic oncology care and there was no
Fig. 1 Reported problems in achieving national data collection in 28
European countries. Legend: Practical support refers to the need for
more funding and staff to support data collection. Infrastructure
includes regional not national datasets, and those countries where
private and university hospitals are not linked, or respiratory and
oncology hospitals that work independently. It also includes the
absence of a single patient identifier, and also those countries without
electronic transfer of data. Political will was stated by 1 co-author as
was concern regarding legal requirements and issues of patient
consent by a further 3 co-authors. Miscellaneous includes quite specific
difficulties encountered in three countries. One co-author stated an
historical lack of interest in epidemiology as a whole as a barrier to
better data collection. Three languages are spoken in one country and
in another, patients are often treated abroad, which makes evaluating
treatment outcomes and follow-up very difficult. Seven countries
stated there were no difficulties in collecting data at a national level
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financial remuneration or pharmaceutical involvement
which could have influenced the results. We therefore
believe this to be an accurate reflection of current prac-
tice across Europe and the first survey to provide a
pan-European picture.
Comparison with published data
There is very little published literature regarding the
variation in data collection across Europe. However, in the
past 25 years, the use of data to evaluate lung cancer care
and make comparisons between areas of the world has
become more common. It was in 1989, during his
presidency of the European Union that Francois
Mitterrand initiated a health programme on cancer pre-
vention and patient information from which the EURO-
CARE papers have all arisen [2, 4, 18]. The EUROCARE
studies are an excellent example of how data have been
used to assess health outcomes, and the results have led to
a change in healthcare funding and structure. Although
the EUROCARE-5 database contains approximately 22
million patients, from 26 countries [19], the actual cover-
age within some of these countries is below 1% popula-
tion, which can introduce geographical bias [20, 21]. And
there is evidence that some countries have incomplete
follow-up data, which for a cancer with a poor prognosis,
such as lung, can lead to falsely reassuring survival results
[22]. Furthermore, these studies lack the level of clinical
detail, such as performance status and stage, which are re-
quired to make direct clinical comparisons between coun-
tries. There is also variation between countries and their
Registries as to whether they rely on histologically con-
firmed cases only, and whether they accept individuals di-
agnosed by death certificate only. In both situations, the
cohort of patients with cancer will be different for those
Registries who accept patients based on a clinical or radio-
logical diagnosis or post-mortem compared with those
Registries which do not. This is particularly relevant for
cancers with a short survival like lung, and could create a
systematic bias causing survival figures to appear better
than they are for the whole population.
The National Lung Cancer Audit (NLCA) in England
was established in 2004, to allow prospective data collec-
tion on all patients given a diagnosis of lung cancer and
mesothelioma. This dataset, validated in 2009 [17], has
shown a year on year improvement in both data acquisi-
tion and data completeness and has been used to assess
inequalities in outcome based on patient and hospital
features [23–30]. There has also been a demonstrable
improvement in key quality performance indicators over
the lifetime of the NLCA [31, 32]. Other European
countries have developed similar systems for data collec-
tion and used these data to evaluate current practice and
address any inequality that may be seen, including
Denmark, Norway and The Netherlands [33–38]. The
Danish Lung Cancer Group wrote clinical guidelines in
1998, and started prospective data collection in 2000.
They have been able to demonstrate that the use of data
collection to monitor guideline adherence, audit per-
formance at the local level and benchmark standards na-
tionally, has led to an objective improvement in lung
cancer outcome measures [39].
The International Cancer Benchmarking Project (ICPB)
was set up in 2009, linking established cancer registration
programmes in 6 countries across 3 continents, in order
to look at cancer outcomes. It is thus limited to only a few
countries. Lung cancer survival has been studied within
this group and variation described, with Denmark and the
UK observed to have lower survival compared to Canada,
Sweden, Norway and Australia [40]. Furthermore, the
International Consortium for Health Outcomes Measure-
ment (ICHOM) published a comprehensive revised data
collection reference guide in April 2015. Their aim is to
create a standardised set of measurements, which can be
used to compare performance between countries, and
allow clinicians to learn from each other, and improve the
provision of lung cancer care [41]. Both the ICBP and
ICHOM require a level of detail of data collection that is
likely to be beyond the capability of many European coun-
tries for the foreseeable future; what is required is a prag-
matic solution.
The expansion of the European Union, and greater
freedom of movement across borders, has led to Euro-
pean ministers beginning to address the issue of collab-
oration between national health services [42]. However,
many European countries have healthcare systems that
have evolved as the political situation changes, for ex-
ample the war of independence in Croatia lead to signifi-
cant damage to the previously thriving cancer services
[43]. It is this variation in socio-political stability that
creates widely disparate healthcare systems. In order to
understand variation in lung cancer outcome, one must
acknowledge the variation in infrastructure, facilities,
and treatments which are available.
In 2006 Ludwig, an Austrian oncologist, recom-
mended a pan-European action plan on cancer, with
bench-marking of the quality and effectiveness of the
various healthcare systems [44]. This survey could form
the background upon which a pan-European core data-
set on thoracic oncology is built. The mechanism would
involve an iterative approach based on what is feasible in
each country, slowly building a more detailed dataset;
the vehicle could be the network already established by
the ERS Taskforce.
Conclusion
Improving the standard of care for our patients should
be the aim of every clinician involved in thoracic oncol-
ogy care, and in order to evaluate different practices
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across Europe we need to be able to understand the pol-
itical and economic setting in which it is based. Data
collection can play an important role in evaluating med-
ical practice and ensuring that whilst a cure for lung
cancer and mesothelioma may not be on the horizon,
the delivery of best available treatments should be realis-
tic. Data collection itself relies on adequate infrastruc-
ture, dedicated personnel, and financial investment in
the information technology to support large scale data-
sets. The results of this study have shown that there is
genuine interest in pan-European data collection and a
pressing need to develop a standardised dataset that is
feasible for all to collect. To this end, a European
Respiratory Society taskforce is developing both an
essential (redacted) and minimum dataset. This is an
important project upon which to build as it will allow
meaningful analyses across Europe that can be used to
drive improvements in care for our patients.
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